Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders

Gabriella Iannuzzo· Gianpaolo De Filippo· Daniela Merlotti· Veronica Abate· Alessio Buonaiuto· Marco Evangelista· Marco Gentile· Alfonso Giaquinto· Tommaso Picchioni· Matteo Nicola Dario Di Minno· Pasquale Strazzullo· Luigi Gennari· Domenico Rendina

Received: 22 August 2020 / Accepted: 15 January 2021 / Published online: 9 February 2021
© The Author(s) 2021

Abstract
Bisphosphonates are the first-choice treatment of osteoporosis and Paget’s disease of bone. Among the bisphosphonates, the non-amino-bisphosphonates, such as clodronic acid, are intracellular converted into toxic analogues of ATP and induce cellular apoptosis whereas the amino-bisphosphonates, such as zoledronic acid, inhibit the farnesyl-diphosphate-synthase, an enzyme of the mevalonate pathway. This pathway regulates cholesterol and glucose homeostasis and is a target for statins. In this retrospective cohort study, we evaluated the effects of an intravenous infusion of zoledronic acid (5 mg) or clodronic acid (1500 mg) on blood lipid (i.e. total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglycerides) and glucose levels in patients with osteoporosis and Paget’s disease of bone. All patients were evaluated before, 1 and 6 months after bisphosphonate treatment. Pagetic and osteoporotic patients treated with zoledronic acid showed a significant reduction in glucose and atherogenic lipids during follow-up whereas these phenomena were not observed after clodronic treatment. The effect on circulating lipid levels was similar in naïve and re-treated Pagetic patients. Zoledronic acid treatment was associated with a reduction in blood glucose and atherogenic lipids in patients with metabolic bone disorders. The extent of change was similar to that obtained with the regular assumption of a low-intensity statin. Further studies are warranted to better evaluate the clinical implications of these observations.

Keywords Paget’s disease of bone · Osteoporosis · Bisphosphonate · Glucose · Cholesterol · Triglycerides

Introduction
Atherosclerosis is a leading cause of cardiovascular morbidity and mortality in Western countries and dyslipidemia is one of the most significant risk factors [1]. Recently, some studies have focused on a possible relationship between metabolic bone disorders (MBDs), cardiovascular diseases (CVDs) and cardiovascular risk factors, primarily dyslipidemia, also considering that the incidence and prevalence of MBDs and CVDs are very high in the adult population worldwide [2, 3]. Osteoporosis (Op) is a MBD characterized by low bone mass and structural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Op affects approximately 200 million people and leads to nearly 9 million fractures annually worldwide [4]. Paget’s disease of bone (PDB) is the second most common MBD after Op worldwide, although marked ethnic and geographical variations in its prevalence has been observed [5–9]. PDB is characterized by increased and disorganized bone turnover, which affects one or more skeletal sites, i.e. monostotic and polyostotic PDB, respectively. The skeletal sites involved by PDB show pathognomonic radiological and scintigraphic changes [9]. Bisphosphonates (BPs) are effective antiresorptive agents currently available for the treatment of several MBDs including Op and PDB [10]. BPs are synthetic, non-hydrolysable analogues of pyrophosphate.
There are two different classes of BPs: non-amino-BPs (nN-BPs) and amino-BPs (N-BPs). The nN-BPs, such as clodronic acid (Clo), are converted intracellularly to methyleno-containing analogues of ATP (AppCCl2p). The accumulation of AppCCl2p in osteoclasts in vitro inhibits bone resorption by inducing osteoclast apoptosis. On the contrary, the N-BPs such as zoledronic acid (Zol) are not metabolized into toxic intracellular analogues of ATP, but act by inhibiting farnesyl-diphosphate-synthase, a key enzyme of the mevalonate pathway. N-BPs are several orders of magnitude more potent than nN-BPs at inhibiting bone resorption in vivo [10, 11]. The mevalonate pathway inhibited by N-BPs has a central role in cholesterol (Chol) biosynthesis and in glucose homeostasis and is a well-known molecular target also for statins, the first-choice treatment for dyslipidemia [12]. In consideration of the above, the objective of this retrospective cohort study was to evaluate if BP treatment affects lipid and glucose blood levels in patients with PDB treated with Zol or Clo. We also analyzed data collected from patients with complicated Op treated with Zol.

Materials and Methods

This retrospective cohort study was performed analyzing the medical records of all consecutive Caucasian patients with PDB [International Classification of Diseases (ICD)-9 code 731.0] and with complicated Op (ICD9 codes 73310-9) referring from January 01, 2009, to December 31, 2018, at the Units of Bone and Mineral Disorders of Siena and Naples, two main national centers for the diagnosis and treatment of MBDs which used a unique approach for clinical classification and management of MBDs and their comorbidities [13, 14]. On their first admission, all patients were informed that (i) their personal data, collected as part of administrative management and hospital care, could be used for health research purposes, under the responsibility of the Federico II University of Naples and of Siena University; (ii) they could withdraw their consent to the use of personal data without providing further explanation at any time and without medical assistance being affected. This, in the form of written informed consent, was obtained from each patient or subject involved in this study.

Data collection was performed from July 01, 2019, to December 31, 2019. The PDB and Op diagnoses were based on published criteria [9, 15]. Only medical records of patients treated with Zol 5 mg intravenously (i.v.) or Clo 1500 mg i.v. were selected for this study [16, 17], to compare N-BP to nN-BP regimens. The BP treatment was administered after supplementation of cholecalciferol and/or calcium in all cases (http://www.agenziafarmaco.gov.it/conten/ nota-79) [18]. Cholecalciferol supplementation and an adequate calcium dietary intake were also prescribed after BP treatment (http://www.agenziafarmaco.gov.it/content/ nota-79) [18, 19]. According to a pre-established collection schedule, the following data were extracted from selected medical records: age, sex, body mass index (BMI), data of infusion, type of drug, glycaemia (sGlu), serum calcium (sCa), total Chol (tChol), low-density lipoproteins-Chol (LDL), high-density lipoprotein-Chol (HDL), triglycerides (TG), 25OH-vitamin D (25OHD), total alkaline phosphatase (ALP), and creatinine (sCrea) levels. These data were collected at the time of BP infusion (T0), after 1 (T1) and 6 months (T6) of treatment. All parameters were expressed according to Système International d’unités excluding ALP serum levels which, in absence of universally accepted reference ranges, were expressed as percentage versus the upper limit of the reference range. Exclusion criteria comprised the following: age lower than 40 years, primary or secondary bone cancers [20, 21], malabsorption syndromes, rheumatoid arthritis, long-term immobilization, moderate to severe chronic kidney disease (estimated glomerular filtration rate (eGFR) ≤ 60 ml/min/1.73 m² [22]), hypothyroidism [23], hyperthyroidism [23], primary hyperparathyroidism [24], hypoparathyroidism, Cushing’s syndrome, chronic liver disease, prostate cancer, pituitary tumors, surgical history of terminal ileal resection, gastrectomy or small bowel bypass, orchietomy, eating disorders, alcoholism, diabetes mellitus, use of statins, anti-diabetes drugs, gonadotropin-releasing hormone agonist, glucocorticoids, anticonvulsants, heparin, vitamin A, cytotoxic drugs, and androgens, and finally subjects with incomplete data collection. The study was approved by the Federico II Ethical Committee.

Statistical Analysis

All statistical analyses were performed using the IBM SPSS Statistics, version 23 (International Business Machines Corporation, Inc., Armonk, NY, USA). Data are expressed as means ± standard deviation for continuous variables and as absolute; percentage values for discrete variables. Contingency table χ² tests and analysis of variance (with Bonferroni correction for multiple comparisons) were used to test for between-group differences in non-parametric and parametric variables, respectively. Differences from baseline after BP treatment were estimated using the Student’s t test or the Wilcoxon test for variables with normal or not-normal distribution, respectively. A p value < 0.05 was considered statistically significant.

Results

According to inclusion and exclusion criteria previously exposed, the medical records of 87 PDB patients treated with Zol (PDB-Zol; men:women 52:35, mean
Table 1 Biochemical parameters of the three study cohorts before and after bisphosphonate treatment

|            | PDB-Zol       | PDB-Clo       | Op-Zol        |
|------------|---------------|---------------|---------------|
|            | T0            | T1            | T6            | T0            | T1            | T6            |
| Crea (μmol/l) | 79.6 ± 31.3   | 81.1 ± 32.1   | 80.3 ± 31.2   | 80.9 ± 29.2   | 82.9 ± 30.3   | 79.6 ± 30.1   |
| Glu (mmol/l) | 5.19 ± 0.58   | 4.98 ± 0.54a  | 4.91 ± 0.52a  | 5.23 ± 0.52   | 5.41 ± 0.51   | 5.27 ± 0.54   |
| tCa (mmol/l) | 2.37 ± 0.13   | 2.29 ± 0.12   | 2.32 ± 0.12   | 2.41 ± 0.14   | 2.29 ± 0.13   | 2.40 ± 0.13   |
| t-chol (mmol/l) | 5.10 ± 1.06  | 4.89 ± 1.02a  | 4.71 ± 1.01a  | 5.29 ± 0.99   | 5.18 ± 1.06   | 5.23 ± 1.05   |
| HDL-chol (mmol/l) | 1.32 ± 0.41  | 1.31 ± 0.42   | 1.31 ± 0.43   | 1.49 ± 0.41   | 1.39 ± 0.42   | 1.39 ± 0.41   |
| LDL-chol (mmol/l) | 3.10 ± 0.96  | 2.98 ± 0.89a  | 2.83 ± 0.86a  | 3.10 ± 0.83   | 3.11 ± 0.82   | 3.16 ± 0.85   |
| TG (mmol/l)  | 1.49 ± 0.80   | 1.32 ± 0.82   | 1.25 ± 0.81a  | 1.53 ± 0.86   | 1.48 ± 0.82   | 1.50 ± 0.81   |
| 25OHDL (nmol/l) | 84.3 ± 18.7  | 82.4 ± 19.1   | 83.7 ± 17.8   | 89.1 ± 18.4   | 88.4 ± 18.1   | 87.1 ± 17.2   |
| ALP (%)     | 155 ± 90b     | 87 ± 32a      | 78 ± 27a      | 148 ± 84b     | 114 ± 58a     | 83 ± 36a      |

Data are expressed as mean ± standard deviation.

- **PDB-Zol** patients with Paget’s disease of bone treated with zoledronic acid, **PDB-Clo** patients with Paget’s disease of bone treated with clodronic acid, **Op-Zol** patients with osteoporosis treated with zoledronic acid. **T0** before zoledronic or clodronic acid treatment, **T1** 1 month after zoledronic or clodronic acid treatment, **T6** 6 months after zoledronic or clodronic acid treatment, Crea creatinine, Glu glycemia, tCa total calcium, t-chol total cholesterol, HDL-chol high-density lipoprotein-cholesterol, LDL-chol low-density lipoprotein-cholesterol, TG triglycerides, 25OHDL 25OH-vitamin D, ALP total alkaline phosphatase.

- *Significantly different compared to T0 (p < 0.05; t test for paired samples)
- *Significantly different compared to Op-Zol patients (p < 0.05; analysis of variance with Bonferroni correction)
and atherogenic lipids levels in subjects without a personal history of diabetes and/or dyslipidemia. These effects were observed both at T1 as well as at T6. This pharmacological property seems to be characteristic of the Zol action on the mevalonate pathway. In fact, no change in circulating glucose and atherogenic lipids was observed in PDB patients treated with Clo, a nN-BP displaying a different mechanism of action [10, 11]. Since Zol and Clo regimens caused a similar reduction in serum ALP levels of PDB patients, it is likely that the observed reduction in the circulating levels of glucose and atherogenic lipids in these patients was not directly linked to the inhibition of abnormal bone turnover. Remarkably, the extent of change observed in circulating atherogenic lipids after Zol infusion is similar in magnitude to that obtained with the regular assumption of a low-intensity statin [25]. Our study results are in agreement with those previously reported in patients treated with Zol for malignancy [26], and strengthen the hypothesis of a link between the N-BP mechanism of action and energetic metabolism in patients with MBD, who are considered at increased risk of CVDs (particularly in case of increased bone turnover, such as PDB and postmenopausal Op) [27]. Indeed, MBD and CVDs may share common pathogenic pathways: in particular, several molecules (such as bone morphogenetic proteins, receptor activator of nuclear factor κB ligand, osteoprotegerin, matrix Gla protein and cathepsins), the parathyroid hormone–vitamin D–calcium–phosphate biological system, oxidized lipids and vitamin K seem implicated in both bone and cardiovascular metabolism [28–30]. In addition, experimental studies support a role

---

Fig. 1 Differences from baseline in blood lipids and glucose levels in patients with Paget’s disease of bone treated for the first time with bisphosphonate (black columns) or in PDB patients previously treated with bisphosphonate (gray columns). Biochemical parameters were measured 1 month and 6 months after zoledronic acid infusion. 

- $t$-chol($T_1$) serum total cholesterol 1 month after infusion,
- $t$-chol($T_6$) serum total cholesterol 6 months after infusion,
- $LDL$-chol($T_1$) low-density lipoprotein-cholesterol 1 month after infusion,
- $LDL$-chol($T_6$) low-density lipoprotein-cholesterol 6 months after infusion,
- $TG$($T_1$) serum triglycerides 1 month after infusion,
- $TG$($T_6$) serum triglycerides 6 months after infusion,
- $HDL$-chol($T_1$) high-density lipoprotein-cholesterol 1 month after infusion,
- $HDL$-chol($T_6$) high-density lipoprotein-cholesterol 6 months after infusion,
- GLU($T_1$) glucose 1 month after infusion,
- GLU($T_6$) glucose 6 months after infusion
of osteocytes in the regulation of lipid metabolism [31]. On clinical grounds, PDB is considered a risk factor for CVDs occurrence, based on the higher prevalence of vascular calcifications and cardiac dysfunction reported in PDB patients [32–35]. The observed reduction in circulating levels of atherogenic lipids and glucose by N-BPs seems to be a pharmacological property that is additive to the previously described capacity of N-BPs to reduce the accumulation of lipids in the atherosclerotic plaque and to prevent vascular calcifications [36–40].

Our results are also in agreement with those reported by Sing and colleagues showing that N-BP treatment is associated with a significant reduction in cardiovascular morbidity and mortality in patients with newly diagnosed hip fracture [41]. Other cohort studies have reported that alendronate, another N-BP, significantly decreases the risk of CV events in a dose-dependent fashion in patients with severe osteoporosis [42–44]. While there is evidence that vitamin D deficiency unfavorably affects glucose and lipid metabolism [29, 45, 46], the changes in glucose and atherogenic lipids observed in our study population upon N-BP treatment were not related to changes in 25OHD serum levels. In fact, all the patients enrolled in this study were treated with cholecalciferol before and after BP treatment, according to the criteria proposed to Italian Health System, to prevent acute-phase reaction and potentially dangerous electrolyte changes after N-BP treatment [18, 19]. Altogether, these epidemiological and experimental observations add further relevance to our study results, which nevertheless are affected by some limitations. The major limits of the study mainly include its retrospective nature, which impairs to establish definitive cause–effect relationships, and a relatively small number of enrolled subjects. It would have been interesting to evaluate whether this pharmacological effect was also observed in patients receiving concomitant antidiabetic and/or statin treatment. In addition, our findings require confirmation in non-Caucasian subjects and in patients using different N-BPs, considering that even small changes to the pharmacological structure of each N-BP may modify the ability to inhibit farnesyl-diphosphate-synthase [47]. In conclusion, the study results suggest a potentially interesting pharmacological effect of N-BPs on glucose and lipid metabolism that adds to their previously described capacity to reduce lipid deposition in the atherosclerotic plaque and to prevent vascular calcification. Further studies are warranted to confirm our observations.

Supplementary Information The online version of this article (https://doi.org/10.1007/s00223-021-00811-w) contains supplementary material, which is available to authorized users.

Author Contributions All authors contributed to the study conception and design. Material preparation and data collection were performed by GI, GDF, DM, VA, AB, ME, MG, AG and TP. The statistical analysis was performed by DR. The first draft of the manuscript was written by GI, GDF and DR. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. DR is the guarantor and attests that all listed authors meet authorship criteria. All authors revised the paper critically for intellectual content and approved the final version. All authors agree to be accountable for the work and to ensure that any questions relating to the accuracy and integrity of the paper are investigated and properly resolved.

Funding Open Access funding provided by Università degli Studi di Napoli Federico II. This was an unfunded project.

Statistics Transparency The manuscript’s guarantor affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Compliance with Ethical Standards

Conflict of interest Gabriella Iannuzzo, Gianpaolo De Filippo, Daniela Merlotti, Veronica Abate, Alessio Buonaiuto, Marco Evangelista, Marco Gentile, Alfonso Giaquinto, Tommaso Picchioni, Matteo Nicola Dario Di Minno, Pasquale Strazzullo, Luigi Gennari, and Domenico Rendina declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Ethical Approval All procedures performed in this study, which involves human participants, were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent Informed consent was obtained from all individual participants included in the study.

Consent to Publish Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lorenzatti AJ, Toth PP (2020) New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol 15:1–9
2. Veronese N, Stubbs B, Crepaldi G, Solmi M, Cooper C, Harvey NC, Regnster JY, Rizzoli R, Civitelli R, Schofield P, Maggi S, Lamb SE (2017) Relationship between low bone mineral density
37. Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537–1538
38. Guney E, Kisakol G, Ozgen AG, Yilmaz C, Kabalak T (2008) Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 29:252–255
39. Gonnelli S, Caffarelli C, Tanzilli L, Pondrelli C, Lucani B, Franci BM, Nuti R (2014) Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone 61:27–32
40. Passeri E, Mazzaccaro D, Sansoni V, Perego S, Nano G, Verdelli C, Lombardi G, Corbetta S (2019) Effects of 12-months treatment with zoledronate or teriparatide on carotid thickness of carotid artery in women with postmenopausal osteoporosis: a pilot study. Int J Immunopathol Pharmacol 33:2058738418822439
41. Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT, Chan EW, Kung AW, Wong IC, Cheung CL (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33:1422–1434
42. Vestergaard P (2012) Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? Calcif Tissue Int 90:22–29
43. Lu P-Y, Hsieh C-F, Tsai Y-W, Huang W-F (2011) Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther 33:1173–1179
44. Kang JH, Keller JJ, Lin HC (2012) A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 23:2551–2557
45. Rendina D, De Filippo G, Strazzullo P (2010) Should vitamin D status be assessed in patients with congestive heart failure? Nutr Metab Cardiovasc Dis 20:627–632
46. Greco EA, Lenzi A, Migliaccio S (2019) Role of hypovitaminosis D in the pathogenesis of obesity-induced insulin resistance. Nutrients 11:E1506
47. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.